Disclosures: Chul Jung: No financial relationships or conflicts of interest

Objective: Previous studies have reported that MIF has protective effects against cerebral injury through inhibiting apoptosis. The purpose of this study is to investigate how MIF, administered at different conditions after neuronal oxygen and glucose deprivation/reoxygenation (OGD/R), can reduce injury in vitro.

Design: In vitro study. Setting : In vitro setting. Participants : N/A

Interventions: Human neuroblastoma cells were incubated in oxygen and glucose deprivation and then returned to normal aerobic environment (OGD/R). MIF was administered with different doses and time. Different doses of MIF (0ng/mL, 1ng/mL, 10ng/mL, 30ng/mL, 60ng/mL, or 100ng/mL) was administered to cells with reperfusion. Cells were assigned to one of seven groups : Normoxia, OGD/R with six different MIF doses. And then, 60ng/mL MIF was administered to each cell culture at different time. Six cell groups were studied : Normoxia, OGD/R, MIF administered at prior to OGD, with OGD, with reperfusion, and during whole processing.

Main Outcome Measures: Cell viability was analyzed with WST-1 assay, and expression of BDNF, MAP2, Caspase3, Bcl2 and Bax was assayed with western blotting.

Results: In dose study, cell viability was significantly increased in MIF groups. It was increased in dose-dependent manner and the highest was observed with 60ng/mL MIF. (p=0.00) In western blotting, expression of BDNF, Bcl2 and MAP2 was higher in MIF groups and the highest was observed with 60ng/mL. Caspase3 and Bax expression didn’t show definite difference. In optimal administration time study, cell viability was significantly increased in MIF groups. However, difference was not observed. It will be planned to do more WST-1 assays and western blottings. Conclusions: MIF administration increased neuronal cell viability after OGD/R injury, and the best effect was observed with dose of 60ng/mL. This result was correlated with western blotting results. Further studies about optimal administration time will be needed for detailed information of use. This study would be base study for MIF studies in vivo.

Level of Evidence: Level V

« Back to AAPM&R Annual Assembly 2020

PM&R Meeting Abstracts - https://pmrjabstracts.org/abstract/optimal-conditions-of-macrophage-migration-inhibitory-factor-mif-for-neuroprotection-after-ischemia-reperfusion-injury-in-vitro/